HER-2/neu detection in fine-needle aspirates of breast cancer - Fluorescence in situ hybridization and immunocytochemical analysis

被引:59
作者
Beatty, BG
Bryant, R
Wang, WC
Ashikaga, T
Gibson, PC
Leiman, G
Weaver, DL
机构
[1] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA
[2] Univ Vermont, Coll Med, Dept Biostat, Burlington, VT 05405 USA
[3] Vermont Reg Canc Ctr, Burlington, VT USA
关键词
HER-2/neu; breast cancer; fine-needle aspirate; immunocytochemistry; immunohistochemistry; fluorescence in situ hybridization;
D O I
10.1309/X8UP920UF4XM1C5C
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We evaluated HER-2 receptor status by immunocytochemical and immunohistochemical analyses and fluorescence in situ hybridization (FISH) in 51 fine-needle aspiration (FNA) specimens together with the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from surgically resected breast cancers. Three fixation methods were compared ethanol, formalin, and CytoLyt-ThinPrep (Cytyc, Boxborough, MA). HER-2 was overexpressed and amplified in 8 (16%) of 51 FFPE specimens. Of the 8 cases, gene amplification was observed in 8 FNA specimens (100%) and overexpression in 2 (25%) ethanol-, 4 (50%) CytoLyt-, and 5 (63%)formalin-fixed FNA specimens. Strong pairwise kappa association between FISH results performed on FNA specimens and FFPE tissue samples (ethanol fixation, kappa = 0.848; ThinPrep, kappa = 0.918) and moderate (ThinPrep, kappa = 0.692; formalin fixation, kappa = 0.667) to poor (ethanol, kappa = 0.300) pairwise kappa agreement between tissue immunohistochemical and FNA immunocytochemical results was demonstrated. We conclude that HER-2 protein expression on cytologic preparations was insufficiently reliable for clinical use, whereas HER-2 gene amplification determined by FISH demonstrated strong and consistent correlation with HER-2 status of FFPE tissue samples.
引用
收藏
页码:246 / 255
页数:10
相关论文
共 46 条
[1]  
Baselga J, 1998, CANCER RES, V58, P2825
[2]   HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer [J].
Bozzetti, C ;
Nizzoli, R ;
Guazzi, A ;
Flora, M ;
Bassano, C ;
Crafa, P ;
Naldi, N ;
Cascinu, S .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1398-1403
[3]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[4]   IMMUNOCYTOCHEMICAL STAINING OF C-ERBB-2 ONCOGENE IN FINE-NEEDLE ASPIRATES OF BREAST-CARCINOMA - A COMPARISON WITH TISSUE-SECTIONS AND OTHER BREAST-CANCER PROGNOSTIC FACTORS [J].
CORKILL, ME ;
KATZ, R .
DIAGNOSTIC CYTOPATHOLOGY, 1994, 11 (03) :250-254
[5]   Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma [J].
Couturier, J ;
Vincent-Salomon, A ;
Nicolas, A ;
Beuzeboc, P ;
Mouret, E ;
Zafrani, B ;
Sastre-Garau, X .
MODERN PATHOLOGY, 2000, 13 (11) :1238-1243
[6]  
DiGiovanna MP, 2002, CANCER RES, V62, P6667
[7]  
Fleiss JL., 1973, STAT METHODS RATES P
[8]   Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites [J].
Gancberg, D ;
Di Leo, A ;
Cardoso, F ;
Rouas, G ;
Pedrocchi, M ;
Paesmans, M ;
Verhest, A ;
Bernard-Marty, C ;
Piccart, MJ ;
Larsimont, D .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1036-1043
[9]   C-ERBB-2 PROTEIN OVEREXPRESSION IN BREAST-CANCER IS A RISK FACTOR IN PATIENTS WITH INVOLVED AND UNINVOLVED LYMPH-NODES [J].
GULLICK, WJ ;
LOVE, SB ;
WRIGHT, C ;
BARNES, DM ;
GUSTERSON, B ;
HARRIS, AL ;
ALTMAN, DG .
BRITISH JOURNAL OF CANCER, 1991, 63 (03) :434-438
[10]   PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].
GUSTERSON, BA ;
GELBER, RD ;
GOLDHIRSCH, A ;
PRICE, KN ;
SAVESODERBORGH, J ;
ANBAZHAGAN, R ;
STYLES, J ;
RUDENSTAM, CM ;
GOLOUH, R ;
REED, R ;
MARTINEZTELLO, F ;
TILTMAN, A ;
TORHORST, J ;
GRIGOLATO, P ;
BETTELHEIM, R ;
NEVILLE, AM ;
BURKI, K ;
CASTIGLIONE, M ;
COLLINS, J ;
LINDTNER, J ;
SENN, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056